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Anti-endotoxin immunotherapy in septic shock
Sir,
In his leading article on this subject (Cohen,
1986) Dr J. Cohen made the following
statement, reported as a personal communica-
tion from M. P. Glauser: "Furthermore,
reexamination of the data from the original
study by Ziegler et al. (1982), suggests that
protection from shock was related to the
generation of the highly conserved Re anti-
bodies, rather than the Re core associated
with E. coli J5". In fact, M. P. Glauser never
reported unpublished data from Ziegler's
study. The mistake was probably a misunder-
standing of part of a paper given at the IXth
International Congress of Infectious and
Parasitic Diseases, Munich, 1986, in which
M. P. Glauser reported data from in-vitro
studies performed in rabbits by one of us
(J. D. Baumgartner) in collaboration with Dr
E. Ziegler. These data revealed that immuniza-
tion of rabbits with Escherichia coli J5
produced antibodies of two types: (1) anti-
bodies to J5 core determinants distal to KDO,
which were mainly type-specific and were
quantitatively predominant, and (2) antibodies
to the lipid A-KDO region, which were less
abundant, but highly cross-reactive
(Baumgartner et al., 1987). The latter anti-
bodies were measured with Re LPS as antigen,
since Re LPS is composed only of lipid A and
KDO, in contrast to J5 LPS which possesses
several additional core sugars. Thus, although
these in-vitro results suggest that antibodies to
lipid A-KDO are more likely to afford cross-
protection after immunization with E. coli J5
than antibodies to J5 LPS core sugars, this has
not been demonstrated clinically.
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Determining the MICs of /Mactams for
Haemophilus.
Sir,
With regard to Dr Yourassowsky and
colleagues' suggestion that the data regarding
Haemophilus influenzae in our recent
publication (Aldridge, Sanders & Marier,
1986) are artefactual, we have the following
comments. We are aware of the pitfalls which
exist with the broth microdilution method
when studying increased inoculum sizes.
Whenever our laboratory performs inoculum
effect studies we routinely culture 10 y\ of the
100 /il in each well. The growth or no growth
of organisms is then used in those cases of
questionable MICs to establish if viable
organisms are present. With reference to the
H. influenzae data in question, where an
inoculum effect was evident the growth of
viable organisms was demonstrated in all
cases. The MBC determinations were not
reported because no standardized MBC
method has yet been approved in the United
States.
We remind Yourassowsky et al. that the
inoculum effect with ampicillin has been
described with /Mactamase positive and
negative strains of H. influenzae at inoculum
sizes equal to or greater than 106 cfu/ml
(Thornsberry & Kirven, 1974). Thus with an
inoculum size of 106 cfu/ml, even in the
presence of a /Mactamase inhibitor, it is not
surprising, as in our study to see a significant
inoculum effect since this has been described
for /Mactamase negative strains. In addition a
number of reports have described a significant
inoculum effect when testing cephalosporins
against /Mactamase positive and negative
strains of H. influenzae (Jones & Preston,
1983; Bell & Washington, 1977).
In our experience doing susceptibility
testing of H. influenzae by the broth micro-
dilution has not produced excessive problems
in MIC endpoint determination nor have we
had problems reproducing results. As a matter
of fact the use of the broth microdilution
method for susceptibility testing of
H. influenzae has been sanctioned by the
National Committee for Clinical Laboratory
Standards (1985) in the United States.
Finally, the differences seen between
Yourassowsky and colleagues' results and ours
cannot be adequately explained at this time.
551
